NALFON Drug Patent Profile

Which patents cover Nalfon, and when can generic versions of Nalfon launch?

Nalfon is a drug marketed by Key Therap and Dista and is included in two NDAs.

The generic ingredient in NALFON is fenoprofen calcium. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the fenoprofen calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nalfon

A generic version of NALFON was approved as fenoprofen calcium by RISING on July 18^th, 2022.

Summary for NALFON

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	97
Patent Applications:	5,732
Drug Prices:	Drug price information for NALFON
What excipients (inactive ingredients) are in NALFON?	NALFON excipients list
DailyMed Link:	NALFON at DailyMed

See drug prices for NALFON

See drug sales revenues for NALFON

Pharmacology for NALFON

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

US Patents and Regulatory Information for NALFON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Key Therap	NALFON	fenoprofen calcium	CAPSULE;ORAL	017604-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Dista	NALFON	fenoprofen calcium	TABLET;ORAL	017710-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Key Therap	NALFON	fenoprofen calcium	CAPSULE;ORAL	017604-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for NALFON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Key Therap	NALFON	fenoprofen calcium	CAPSULE;ORAL	017604-003	Approved Prior to Jan 1, 1982
Dista	NALFON	fenoprofen calcium	TABLET;ORAL	017710-001	Approved Prior to Jan 1, 1982
Key Therap	NALFON	fenoprofen calcium	CAPSULE;ORAL	017604-002	Approved Prior to Jan 1, 1982

International Patents for NALFON

See the table below for patents covering NALFON around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	141439
Philippines	9478	4-PHENOXYPHENYL ALKANOIC ACID DERIVATIVE
South Africa	6905611

NALFON Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for NALFON (Fenoprofen Calcium)

Introduction

NALFON, or fenoprofen calcium, is a nonsteroidal anti-inflammatory drug (NSAID) widely used to treat pain and inflammation caused by arthritis and other conditions. To understand the market dynamics and financial trajectory of NALFON, it is essential to delve into various aspects of the non-opioid pain treatment market, the generic drug industry, and specific factors influencing NALFON's market position.

Global Non-Opioid Pain Treatment Market Overview

The global non-opioid pain treatment market is experiencing significant growth, driven by increasing R&D investments, supportive government and private initiatives, and a rising demand for safer pain relief alternatives to opioids. The market was valued at USD 45.32 billion in 2024 and is projected to grow at a CAGR of 7.69% from 2025 to 2030, reaching USD 70.30 billion by 2030[1].

Dominance of NSAIDs

NSAIDs, including NALFON, dominate the non-opioid pain treatment market, accounting for 54.94% of the global revenue in 2024. This dominance is due to their wide availability, easy accessibility, and high prescription rates. In the U.S., over 70 million NSAID prescriptions are issued annually, and Americans consume over 30 billion doses of NSAIDs each year[1].

Market Segmentation

Pain Outlook

The market is segmented based on the type of pain treated, including post-operative pain, cancer pain, chronic pain, and other types. Chronic pain, in particular, is a significant driver due to the increasing prevalence of chronic and inflammatory diseases[1].

Route of Administration

NALFON is administered orally, which is the most common route of administration in the non-opioid pain treatment market. Other routes include topical and injectable, but oral administration remains the most prevalent[1].

Distribution Channels

Retail pharmacies dominate the distribution channels, accounting for 54.39% of the market revenue in 2024. Major retail pharmacies like CVS Health, Walgreens Boots Alliance, and Rite Aid Corp. are key providers of non-opioid analgesics, including NALFON[1].

Competitive Landscape

The non-opioid pain treatment market is highly competitive, with key players such as Novartis AG, Teva Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd, and Pfizer Inc. These companies invest heavily in R&D to develop innovative pain relief drugs and benefit from supportive regulatory and reimbursement policies[1].

Generic Drug Industry Dynamics

NALFON, as a generic drug, is subject to the dynamics of the generic drug industry. Generic drug prices tend to fall with an increasing number of competitors but remain above long-run marginal costs until there are eight or more competitors. This competition can lead to lower prices and increased market penetration for generic NSAIDs like NALFON[3][4].

Financial Trajectory

Revenue Growth

Given the dominance of NSAIDs in the non-opioid pain treatment market and the growing demand for safer pain relief options, NALFON is likely to see continued revenue growth. The market's CAGR of 7.69% from 2025 to 2030 indicates a robust financial trajectory for NALFON and similar NSAIDs[1].

Pricing Dynamics

As more generic versions of NSAIDs enter the market, prices are expected to decline. However, until there are eight or more competitors, prices will remain above long-run marginal costs. This pricing dynamic can impact the profitability of NALFON but also ensures its continued availability and affordability for patients[3][4].

Regional Market Performance

North America

In North America, particularly in the U.S., NALFON benefits from a large and established market for NSAIDs. The high prescription rates and over-the-counter usage of NSAIDs in this region contribute significantly to the revenue of NALFON[1].

Latin America

In Latin America, countries like Brazil are driving growth in the non-opioid pain treatment market. The increasing prevalence of chronic conditions such as arthritis and back pain, along with government initiatives to improve healthcare infrastructure, are expected to boost the demand for NALFON and other NSAIDs in this region[1].

Challenges and Risks

Adverse Effects

NALFON, like other NSAIDs, carries risks of serious cardiovascular and gastrointestinal events. These risks can impact patient compliance and may lead to regulatory scrutiny or changes in prescribing practices[2].

Regulatory Environment

Changes in regulatory policies, such as increased FDA scrutiny of generic drug applications, can affect the cost and complexity of bringing generic drugs like NALFON to market. However, simultaneous approvals of multiple generic entrants can lead to earlier competition and lower prices[4].

Key Takeaways

• Market Growth: The non-opioid pain treatment market, driven by NSAIDs like NALFON, is expected to grow significantly, reaching USD 70.30 billion by 2030.
• Competitive Landscape: The market is highly competitive, with major pharmaceutical companies investing in R&D and benefiting from supportive policies.
• Pricing Dynamics: Generic drug prices, including those of NALFON, tend to fall with increasing competition but remain above long-run marginal costs until there are eight or more competitors.
• Regional Performance: North America and Latin America are key regions driving the growth of NALFON, with Brazil being a significant market in Latin America.
• Challenges: NALFON faces challenges related to adverse effects and regulatory changes, which can impact its market position.

FAQs

Q: What is the current market size of the non-opioid pain treatment market?

The global non-opioid pain treatment market size was estimated at USD 45.32 billion in 2024[1].

Q: What is the projected growth rate of the non-opioid pain treatment market?

The market is projected to grow at a CAGR of 7.69% from 2025 to 2030[1].

Q: Which segment dominates the non-opioid pain treatment market?

The Non-steroidal Anti-Inflammatory Drugs (NSAIDs) segment dominates the market, accounting for 54.94% of the global revenue in 2024[1].

Q: What are the common adverse effects associated with NALFON?

Common adverse effects include gastrointestinal issues such as dyspepsia, nausea, and abdominal pain, as well as cardiovascular and special senses-related issues[2].

Q: How does competition affect the pricing of generic drugs like NALFON?

Generic drug prices fall with the number of competitors but remain above long-run marginal costs until there are eight or more competitors[3][4].

Sources

1. Grand View Research: Non-opioid Pain Treatment Market | Industry Report, 2030
2. RxList: Nalfon (Fenoprofen Calcium): Side Effects, Uses, Dosage
3. ResearchGate: Generic Drug Industry Dynamics
4. Federal Trade Commission: Generic Drug Industry Dynamics
5. DailyMed: Fenoprofen Calcium Capsules, USP 200 mg and 400 mg